Citigroup Initiates Coverage On Sage Therapeutics with Sell Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Citigroup has initiated coverage on Sage Therapeutics with a Sell rating and a price target of $8.
May 29, 2024 | 10:43 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citigroup has initiated coverage on Sage Therapeutics with a Sell rating and a price target of $8, which is significantly lower than its current trading price.
The Sell rating and the low price target of $8 from a major financial institution like Citigroup are likely to negatively impact investor sentiment and could lead to a decline in Sage Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100